# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allow...
The FDA's Fast track designation is aimed to facilitate the development and expedite the review of drugs to treat serious c...
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors...
JP Morgan analyst Jessica Fye maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $194 to $200.
Citigroup analyst Yigal Nochomovitz maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $269 to $288.